Index -
P/E -
EPS (ttm) -4.36
Insider Own 4.32%
Shs Outstand 85.74M
Perf Week 0.13%
Market Cap 3.77B
Forward P/E -
EPS next Y -4.05
Insider Trans -2.43%
Shs Float 82.07M
Perf Month 11.38%
Income -366.25M
PEG -
EPS next Q -1.23
Inst Own 69.38%
Short Float 25.35%
Perf Quarter -16.12%
Sales 37.31M
P/S 100.91
EPS this Y -10.94%
Inst Trans 2.81%
Short Ratio 9.46
Perf Half Y -2.17%
Book/sh 22.53
P/B 1.95
EPS next Y 15.91%
ROA -16.38%
Short Interest 20.81M
Perf Year -44.38%
Cash/sh 22.20
P/C 1.98
EPS next 5Y 15.85%
ROE -19.20%
52W Range 36.52 - 76.86
Perf YTD 11.52%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -17.13%
52W High -42.89%
Beta 1.74
Dividend TTM -
Quick Ratio 22.07
Sales past 5Y 31550.17%
Gross Margin -247.24%
52W Low 20.19%
ATR (14) 2.82
Dividend Ex-Date -
Current Ratio 22.07
EPS Y/Y TTM -123.71%
Oper. Margin -1250.38%
RSI (14) 49.59
Volatility 6.34% 6.83%
Employees 393
Debt/Eq 0.12
Sales Y/Y TTM -89.95%
Profit Margin -981.54%
Recom 1.97
Target Price 80.33
Option/Short Yes / Yes
LT Debt/Eq 0.11
EPS Q/Q -139.74%
Payout -
Rel Volume 0.47
Prev Close 42.37
Sales Surprise 343.09%
EPS Surprise 63.35%
Sales Q/Q -82.26%
Earnings Feb 11 AMC
Avg Volume 2.20M
Price 43.90
SMA20 -3.65%
SMA50 2.66%
SMA200 -9.90%
Trades
Volume 933,455
Change 3.60%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-14-25 Upgrade
Evercore ISI
In-line → Outperform
$60 → $99
Feb-12-25 Upgrade
TD Cowen
Sell → Hold
$35
Feb-03-25 Initiated
H.C. Wainwright
Buy
$65
Aug-06-24 Reiterated
Needham
Buy
$88 → $84
Aug-02-24 Initiated
Rodman & Renshaw
Buy
$90
Jun-28-24 Resumed
Guggenheim
Neutral
Feb-15-24 Initiated
Wolfe Research
Peer Perform
Dec-11-23 Downgrade
TD Cowen
Market Perform → Underperform
$30
Oct-17-23 Downgrade
Cantor Fitzgerald
Overweight → Neutral
Sep-27-23 Initiated
Mizuho
Buy
$82
Aug-17-23 Upgrade
Citigroup
Neutral → Buy
May-30-23 Initiated
William Blair
Outperform
$75
Apr-13-23 Initiated
Cantor Fitzgerald
Overweight
$72
Mar-21-23 Initiated
Bernstein
Mkt Perform
$44
Mar-17-23 Initiated
Bryan Garnier
Buy
$70
Mar-07-23 Initiated
Robert W. Baird
Neutral
$46
Oct-11-22 Initiated
Morgan Stanley
Underweight
$37
Aug-09-22 Downgrade
Barclays
Overweight → Equal Weight
$99 → $88
Jun-23-22 Downgrade
Evercore ISI
Outperform → In-line
$66 → $60
Jun-17-22 Initiated
BMO Capital Markets
Outperform
$98
Show Previous Ratings
Mar-11-25 08:35AM
(Pharmaceutical Technology)
Mar-03-25 09:00AM
Feb-28-25 03:15AM
Feb-26-25 08:00AM
Feb-24-25 10:00AM
01:34PM
Loading…
Feb-23-25 01:34PM
Feb-20-25 12:01PM
09:00AM
Feb-16-25 05:34AM
Feb-15-25 02:00AM
Feb-14-25 12:20PM
10:38AM
Feb-12-25 06:37PM
11:26AM
10:25AM
05:10PM
Loading…
Feb-11-25 05:10PM
04:01PM
Feb-10-25 05:50PM
06:15AM
Feb-06-25 08:13PM
Feb-04-25 06:00PM
Jan-30-25 01:50PM
Jan-29-25 05:50PM
08:00AM
Jan-24-25 06:00PM
Jan-23-25 08:30AM
04:15AM
Jan-17-25 11:16AM
Jan-16-25 08:00AM
03:15AM
06:00PM
Loading…
Jan-14-25 06:00PM
04:34AM
Jan-13-25 07:00AM
Jan-09-25 04:20AM
Jan-08-25 08:30AM
Jan-07-25 06:00PM
08:00AM
07:19AM
Dec-31-24 05:50PM
Dec-30-24 03:47PM
Dec-29-24 06:36AM
Dec-26-24 06:00PM
Dec-22-24 12:25PM
Dec-20-24 09:30AM
Dec-17-24 05:29AM
Dec-14-24 09:45AM
Dec-12-24 12:37PM
Dec-11-24 11:45AM
Dec-09-24 12:00PM
Dec-07-24 08:45AM
Dec-06-24 12:00PM
Dec-05-24 11:30AM
05:27AM
Dec-02-24 05:44PM
Nov-30-24 04:35AM
Nov-24-24 05:47AM
Nov-23-24 06:30AM
Nov-21-24 05:15PM
Nov-19-24 07:03PM
Nov-18-24 06:53AM
Nov-17-24 05:11PM
Nov-16-24 06:00AM
Nov-15-24 05:45AM
Nov-14-24 08:30AM
Nov-13-24 06:30AM
Nov-08-24 05:20PM
(Yahoo Finance Video)
+6.28%
01:22PM
Nov-07-24 08:00AM
Nov-06-24 12:42PM
09:55AM
Nov-05-24 10:10AM
09:01AM
05:00AM
Nov-04-24 09:35AM
09:30AM
Nov-02-24 10:00AM
Oct-31-24 04:02AM
Oct-26-24 06:32AM
Oct-25-24 05:50PM
Oct-22-24 11:50AM
Oct-21-24 06:00PM
09:55AM
Oct-19-24 07:30AM
Oct-16-24 03:47PM
09:45AM
Oct-15-24 06:00PM
Oct-13-24 06:30AM
Oct-12-24 08:30AM
Oct-08-24 06:00PM
Oct-05-24 04:25AM
Oct-04-24 07:13PM
(Pharmaceutical Technology)
Oct-02-24 06:00PM
05:00AM
04:55AM
Sep-25-24 06:00PM
Sep-21-24 07:36AM
Sep-19-24 05:50PM
04:33AM
Sep-18-24 06:00PM
Sep-12-24 08:45AM
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Greene John Director Feb 26 '25 Buy 44.85 7,000 313,948 7,000 Feb 28 05:35 PM Kulkarni Samarth Chief Executive Officer Feb 19 '25 Sale 55.20 18,360 1,013,564 171,613 Feb 21 05:35 PM Kulkarni Samarth Chief Executive Officer Feb 18 '25 Sale 55.05 11,640 640,782 196,901 Feb 19 05:35 PM Kulkarni Samarth Chief Executive Officer Feb 19 '25 Sale 52.80 6,928 365,798 189,973 Feb 19 05:35 PM Bruno Julianne Chief Operating Officer Feb 19 '25 Sale 52.80 333 17,582 7,062 Feb 19 05:35 PM KASINGER JAMES R. General Counsel and Secretary Feb 18 '25 Sale 53.85 9,595 516,691 73,002 Feb 19 05:35 PM KASINGER JAMES R. General Counsel and Secretary Feb 19 '25 Sale 52.80 1,947 102,802 74,880 Feb 19 05:35 PM Samarth Kulkarni Officer Feb 18 '25 Proposed Sale 52.22 45,000 2,349,900 Feb 18 05:35 PM Kulkarni Samarth Chief Executive Officer Dec 24 '24 Option Exercise 16.21 13,751 222,904 195,291 Dec 27 05:35 PM Kulkarni Samarth Chief Executive Officer Dec 02 '24 Sale 55.10 15,000 826,564 181,540 Dec 04 05:35 PM Kulkarni Samarth Chief Executive Officer Nov 11 '24 Sale 55.62 30,000 1,668,678 196,540 Nov 13 05:35 PM KASINGER JAMES R. General Counsel and Secretary Oct 14 '24 Sale 46.28 1,089 50,399 62,597 Oct 15 06:00 PM Kulkarni Samarth Chief Executive Officer Oct 14 '24 Sale 46.28 4,293 198,680 226,540 Oct 15 06:00 PM Bruno Julianne Chief Operating Officer Jun 21 '24 Sale 56.09 3,366 188,799 6,745 Jun 24 05:35 PM Kulkarni Samarth Chief Executive Officer Apr 15 '24 Option Exercise 19.12 19,582 374,408 227,704 Apr 17 05:45 PM Kulkarni Samarth Chief Executive Officer Apr 15 '24 Sale 59.91 19,582 1,173,232 208,122 Apr 17 05:45 PM Prasad Raju Chief Financial Officer Mar 15 '24 Sale 72.69 3,524 256,160 6,476 Mar 18 05:45 PM Kulkarni Samarth Chief Executive Officer Mar 15 '24 Option Exercise 19.12 20,000 382,400 228,122 Mar 18 05:45 PM Kulkarni Samarth Chief Executive Officer Mar 15 '24 Sale 72.48 20,000 1,449,628 208,122 Mar 18 05:45 PM
Index S&P 500
P/E 10.51
EPS (ttm) 15.56
Insider Own 0.58%
Shs Outstand 251.34M
Perf Week -9.63%
Market Cap 41.14B
Forward P/E 10.30
EPS next Y 15.88
Insider Trans 0.00%
Shs Float 250.15M
Perf Month -16.32%
Income 3.91B
PEG 14.39
EPS next Q 3.37
Inst Own 84.34%
Short Float 2.12%
Perf Quarter -8.77%
Sales 23.68B
P/S 1.74
EPS this Y -21.81%
Inst Trans -1.44%
Short Ratio 3.15
Perf Half Y 22.64%
Book/sh 67.12
P/B 2.44
EPS next Y 14.59%
ROA 2.65%
Short Interest 5.30M
Perf Year 34.84%
Cash/sh -
P/C -
EPS next 5Y 0.73%
ROE 24.68%
52W Range 119.31 - 205.76
Perf YTD -5.61%
Dividend Est. 2.86 (1.75%)
P/FCF 5.04
EPS past 5Y 14.28%
ROI 13.95%
52W High -20.53%
Beta 1.23
Dividend TTM 2.80 (1.71%)
Quick Ratio -
Sales past 5Y 12.10%
Gross Margin -
52W Low 37.05%
ATR (14) 7.37
Dividend Ex-Date Feb 20, 2025
Current Ratio 0.20
EPS Y/Y TTM 45.76%
Oper. Margin 22.63%
RSI (14) 33.27
Volatility 3.99% 3.72%
Employees 21000
Debt/Eq 0.91
Sales Y/Y TTM 15.25%
Profit Margin 16.50%
Recom 2.21
Target Price 213.69
Option/Short Yes / Yes
LT Debt/Eq 0.56
EPS Q/Q 427.97%
Payout 15.81%
Rel Volume 1.16
Prev Close 157.77
Sales Surprise 8.50%
EPS Surprise 41.65%
Sales Q/Q 10.63%
Earnings Jan 22 AMC
Avg Volume 1.68M
Price 163.51
SMA20 -11.49%
SMA50 -12.75%
SMA200 5.27%
Trades
Volume 1,750,243
Change 3.64%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-13-25 Upgrade
UBS
Neutral → Buy
$150 → $239
Jan-06-25 Upgrade
Barclays
Equal Weight → Overweight
$137 → $186
Jun-07-24 Initiated
BTIG Research
Neutral
Feb-08-24 Upgrade
Morgan Stanley
Equal-Weight → Overweight
$105 → $133
Jan-19-24 Downgrade
HSBC Securities
Buy → Hold
$121 → $107
Jan-10-24 Initiated
Deutsche Bank
Hold
$140
Jan-03-24 Upgrade
Piper Sandler
Neutral → Overweight
$104 → $129
Dec-20-23 Upgrade
Citigroup
Neutral → Buy
$93 → $133
Dec-06-23 Upgrade
BofA Securities
Neutral → Buy
$94 → $116
Nov-15-23 Initiated
Barclays
Equal Weight
$99
Nov-01-23 Initiated
TD Cowen
Outperform
$100
Oct-13-23 Initiated
HSBC Securities
Buy
$104
Aug-24-23 Upgrade
Wolfe Research
Peer Perform → Outperform
$104
Jul-21-23 Downgrade
Piper Sandler
Overweight → Neutral
$130 → $112
Mar-15-23 Upgrade
BofA Securities
Underperform → Neutral
$107
Feb-08-23 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$96
Jan-06-23 Downgrade
Barclays
Overweight → Equal Weight
$115 → $120
Dec-13-22 Downgrade
BofA Securities
Buy → Underperform
Nov-21-22 Initiated
UBS
Neutral
$120
Oct-26-22 Upgrade
Morgan Stanley
Equal-Weight → Overweight
$104 → $116
Show Previous Ratings
Today 03:06PM
Mar-11-25 05:30AM
(The Wall Street Journal)
Mar-10-25 05:17PM
(Yahoo Finance Video) -6.29%
05:03PM
04:00AM
11:30PM
Loading…
Mar-04-25 11:30PM
Mar-03-25 02:52PM
(Investor's Business Daily)
Feb-21-25 11:30AM
Feb-20-25 12:00PM
Feb-19-25 11:37AM
Feb-18-25 02:52PM
02:45PM
Feb-13-25 12:50PM
Jan-28-25 08:36AM
Jan-25-25 09:11AM
05:30AM
Loading…
05:30AM
(The Wall Street Journal)
Jan-24-25 02:02AM
Jan-23-25 11:16AM
Jan-22-25 05:27PM
04:30PM
09:06AM
Jan-21-25 07:00PM
04:27PM
Jan-20-25 09:58AM
Jan-19-25 05:00AM
Jan-15-25 10:00AM
Jan-14-25 07:31PM
09:46AM
(The Wall Street Journal)
09:46AM
(The Wall Street Journal)
Jan-08-25 12:10PM
05:30AM
Loading…
Jan-05-25 05:30AM
(The Wall Street Journal)
Dec-31-24 05:15PM
(The Wall Street Journal)
Dec-29-24 05:30AM
(The Wall Street Journal)
Dec-26-24 04:15PM
05:00AM
Dec-20-24 07:45AM
(Retail Banker International)
Dec-19-24 08:15AM
Dec-18-24 10:08PM
Dec-17-24 09:00PM
(The Wall Street Journal)
04:15PM
Dec-11-24 06:06AM
Dec-10-24 09:44AM
08:00AM
Nov-29-24 07:22AM
Nov-25-24 06:52PM
(The Wall Street Journal)
06:06PM
03:26PM
(The Wall Street Journal)
Nov-20-24 08:19AM
Nov-18-24 07:15AM
Nov-15-24 11:30AM
08:00AM
Nov-13-24 06:19PM
Nov-08-24 08:54AM
(The Wall Street Journal)
Nov-07-24 05:00AM
Nov-06-24 07:42PM
(Morningstar Research) +20.22%
04:43PM
03:07PM
(The Wall Street Journal)
02:33PM
02:18PM
12:10PM
11:17AM
11:10AM
Nov-05-24 05:00PM
Oct-30-24 07:10AM
Oct-28-24 12:00PM
Oct-25-24 11:38PM
04:45PM
02:39PM
01:39PM
(Investor's Business Daily)
10:51AM
(The Wall Street Journal)
04:00AM
Oct-24-24 06:34PM
10:46AM
Oct-23-24 02:16PM
12:50PM
Oct-18-24 03:02AM
Oct-16-24 07:43PM
(The Wall Street Journal)
05:30PM
04:22PM
Oct-15-24 03:59PM
11:05AM
10:06AM
Oct-13-24 06:00AM
Oct-09-24 10:00AM
Oct-08-24 10:17AM
Sep-26-24 05:29PM
04:05PM
Sep-21-24 04:30AM
Sep-18-24 07:41AM
Sep-14-24 03:14PM
Sep-10-24 12:30PM
(The Wall Street Journal)
Aug-26-24 04:09PM
Aug-25-24 10:30PM
07:18AM
02:16AM
Aug-19-24 09:50PM
Aug-16-24 11:30AM
Aug-14-24 01:53PM
Aug-12-24 11:31AM
Aug-08-24 09:00AM
Discover Financial Services is a holding company. It operates under the Digital Banking and Payment Services segments. The Digital Banking segment focuses on consumer banking and lending products, specifically Discover-branded credit cards issued to individuals on the Discover Network and other consumer banking products and services including private student loans, personal loans, home loans, and deposit products. The Payment Services segment includes PULSE, Diners Club, and the Network Partners business, which provides payment transaction processing and settlement services on the Discover Global Network. The company was founded in 1960 and is headquartered in Riverwoods, IL.
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite